View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
March 19, 2021

Viral vector shortage is a problem for AZ’s and J&J’s Covid-19 vaccines, gene therapies

As the latest wave of Covid-19 vaccines—those from AstraZeneca (Oxford, UK) and Johnson and Johnson (New Brunswick, NJ, US)—are approved in the EU and poised for likely approval in the US, the news highlights the lack of manufacturing capacity for viral vectors, a vital step in making these vaccines.

By GlobalData Healthcare

As the latest wave of Covid-19 vaccines—those from AstraZeneca (Oxford, UK) and Johnson and Johnson (New Brunswick, NJ, US)—are approved in the EU and poised for likely approval in the US, the news highlights the lack of manufacturing capacity for viral vectors, a vital step in making these vaccines.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

AstraZeneca and Johnson and Johnson’s vaccines are recombinant vector vaccines, a different molecule type from the first wave of mRNA-based Covid-19 vaccines from Pfizer (New York, NY, US)/BioNTech (Mainz, Germany) and Moderna (Cambridge, MA, US), which were granted FDA emergency use approvals (EUAs) in December.

Recombinant vector vaccines use an attenuated virus to introduce microbial DNA to cells of the body. This vaccine molecule subtype received its first approvals last year: two Johnson and Johnson Ebola vaccines were approved by the European Medicines Agency (EMA), and one Covid-19 vaccine—Gamaleya Federal Research Centre of Epidemiology and Microbiology’s Gam-Covid-Vac—was approved in Russia.

Because recombinant vector vaccines use a virus as a vector for DNA delivery, they compete for the world’s limited virus production capacity with gene therapies and gene-modified cell therapies, both of which also use viral vectors.

Even before the approval of recombinant vector vaccines, the pharma industry was struggling to manufacture sufficient viral vectors to meet the needs of the handful of marketed gene therapies and growing number of clinical trials. Compounding this capacity crunch, there are many more gene therapies in late-stage pipeline development that GlobalData expects to hit the market in the next few years.

A forthcoming GlobalData PharmSource Trend Report shows that there are 3,171 gene therapy or recombinant vector vaccine pipeline products in active development between the Discovery and Pre-Registration stages. As shown by the graph below, the majority of these—2,736— are gene therapies, and 434 are recombinant vector vaccines.

Marketed Therapies Also Require Viral Vectors

As shown by the tables below, there are currently 14 gene therapies and recombinant vector vaccines approved and marketed in the EU, Japan, US and/or UK.

AstraZeneca’s Covid-19 vaccine was approved by the EU on 29 January. It received an EUA in the UK and is being administered to the public, but has not received full UK Medicines and Healthcare products Regulatory Agency (MHRA) approval.

Johnson and Johnson’s JNJ-78436735 Covid-19 vaccine was approved by the EU on 11 March and has received an EUA in the US.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology